Vancouver, BC — April 29, 2022 — Telescope Innovations Corp. (“Telescope” or the “Company”) (CSE: TELI), a chemical technology company, announces that during its Annual General and Special Meeting (the “Meeting”) held on April 28, 2022, shareholders approved all agenda items presented, including the election of management’s nominees to serve as directors of the Company: Prof. Jason Hein, Robert Mintak, James Andrew Robinson and Ali Pejman.
In addition, an additional nominee director, Mr. Henry Dubina, was nominated from the floor and subsequently was elected as an additional director of the Company.
“We are thrilled to have Henry on our board of directors and we look forward to having him share his years of professional and business experience with us”, stated Jason Hein, CEO.
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. A key area of application for these tools is the development of scalable manufacturing processes for mental health medicines in the under-utilized tryptamine class of compounds, including psychedelic therapeutics. Telescope also applies these toolsets to resolve inefficiencies in industrial process chemistry and manufacturing. Our aim is to bring modern chemical solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Jason Hein, Chief Executive Officer
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.